ArticleProceedings of the National Academy of Sciences of the United States of America2020
Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/
Open access · greenAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 97 citations in OpenAlex.
- Menin Inhibitors in Acute Myeloid Leukemia: Clinical Integration, Resistance, and the Path Beyond Monotherapy.Cancers · 2026Review
- Modeling KRAS mutations in KMT2A::MLLT3 acute myeloid leukemia promotes leukemic progression and transcriptional rewiring.Leukemia · 2026Article
- Review
- Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML: A Multicenter Study of the ECLA Group.American journal of hematology · 2026Article
- Article
- DNA methylation-based classification of hematolymphoid neoplasms.Blood advances · 2026Article
- Evaluation of acute myeloid leukemia using genomic proximity mapping-based next generation cytogenomics.Haematologica · 2026Article
- Review
- Acute Myeloid Leukemias with Alterations of Lysine Methyltransferase 2A (KMT2A): Recent Therapeutic Developments.Cancers · 2026Review
- [Clinical characteristics and prognostic analysis of adult KMT2A-associated acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- A novel human acute myeloid leukemia cell line SDEY-AML1 with KMT2A: MLLT3, IKZF1: EVX1 fusions exhibits high tumorigenicity in NSG mice.Scientific reports · 2026Article
- Article
- CharacterizingCancers · 2026Article
- A Systematic, Evidence-Based Workflow for Classifying KMT2A Fusions in Acute Myeloid Leukemia.The Journal of molecular diagnostics : JMD · 2025Article
- RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm.Blood advances · 2025Article
- Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements.Leukemia · 2025Article
- Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group.Blood cancer journal · 2025Article
- Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilities.International journal of hematology · 2025Article
- [Screening of MLL fusion genes and rare breakpoint cases in patients with acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Pbx3-mediated suppression of type I interferon response contributes to leukemia progression driven by MLL-AF9.Cancer gene therapy · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Marius BillThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; marius.bill@osumc.edu krzysztof.mrozek@osumc.edu Albert.delaChapelle@osumc.edu.
Krzysztof MrózekThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; marius.bill@osumc.edu krzysztof.mrozek@osumc.edu Albert.delaChapelle@osumc.edu.
Jessica KohlschmidtThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Ann-Kathrin EisfeldThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Christopher J WalkerThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Deedra NicoletThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Dimitrios PapaioannouThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
James S BlachlyThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Shelley OrwickThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.ORCID 0000-0002-4537-1409
Andrew J CarrollDepartment of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294.
Jonathan E KolitzNorthwell Health Cancer Institute, Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY 11042.
Bayard L PowellDepartment of Internal Medicine, Section on Hematology & Oncology, Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157.
Richard M StoneDepartment of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, MA 02215.
Albert de la ChapelleHuman Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210; marius.bill@osumc.edu krzysztof.mrozek@osumc.edu Albert.delaChapelle@osumc.edu.ORCID 0000-0001-9345-9248
John C ByrdThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
Clara D BloomfieldThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
The Ohio State University · USAlliance for Clinical Trials in Oncology · USAtrium Health Wake Forest Baptist · USCancer Genetics (United States) · USNorthwell Health · USUniversity of Alabama at Birmingham · US
Funding
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MTHE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0MSPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 2009 to 2013
$11.2MTargeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI ASTER, JON C. · 2017 to 2021
$10.6MCancer and Leukemia Group B - Leukemia Correlative SciencesU10CA101140 · NCI · OHIO STATE UNIVERSITY · PI MARCUCCI, GUIDO · 2003 to 2013
$10.3MOSU as a Network Lead Academic Participating Site for the NCI NCTNUG1CA233331 · NCI · OHIO STATE UNIVERSITY · PI John L. Hays, Dwight H. Owen · 2019 to 2026
$8.9MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6MTargeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6MCancer and Leukemia Group B - The Ohio State UniversityU10CA077658 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 1998 to 2013
$6.0MITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" TherapiesUG1CA233338 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2019 to 2025
$4.5MNCI NIH HHS P30 CA016058NCI NIH HHS P50 CA140158NCI NIH HHS P50 CA206963NCI NIH HHS R35 CA197734NCI NIH HHS U10 CA077658NCI NIH HHS U10 CA101140NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180861NCI NIH HHS U10 CA180882NCI NIH HHS U24 CA196171NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233331NCI NIH HHS UG1 CA233338
Abstract
Balanced rearrangements involving the
Indexed as
AdolescentAdultAgedChromosome AberrationsFemaleGene RearrangementHistone-Lysine N-MethyltransferaseHumansJacobsen Distal 11q Deletion SyndromeKaryotypingLeukemia, Myeloid, AcuteMaleMiddle AgedMutationMyeloid-Lymphoid Leukemia ProteinTranslocation, GeneticHistone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia Proteinacute myeloid leukemiaclinical outcomegene mutationsKMT2Anext-generation sequencing
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.